- Ixekizumab is associated with improvements in National Psoriasis Foundation (NPF)-defined treatment targets for patients with plaque psoriasis.
Why this matters
- The ability of existing therapies to meet treatment targets has not been well studied.
- Ixekizumab every 2 weeks (Q2W) was associated with an acceptable response (AR) rate of 73.9% and a target response (TR) rate of 51.8% in pooled analysis of the UNCOVER-1, UNCOVER-2, and UNCOVER-3 trials.
- Etanercept was associated with a 35.7% AR rate and a 14.9% TR rate (P<.001 vs ixekizumab for both>
- Ixekizumab Q2W was associated with an AR rate of 68.4% and a TR rate of 50.7% in the IXORA-A trial.
- Ustekinumab was associated with an AR rate of 38.6% and a TR rate of 24.1% (P<.0001 vs ixekizumab for both>
- 2701 patients with plaque psoriasis from the UNCOVER studies and 302 from the IXORA-S study were included in post-hoc pooled analysis.
- The NPF defines AR as body surface area affected (BSA) ≤3% or BSA improvement ≥75% at 12 weeks of treatment and TR as BSA ≤1% at 12 weeks and every 6 months thereafter.
- Funding: Eli Lilly and Company.
- Post-hoc analyses.
- Trial data may not reflect real-world practice.